CoChat
Sign Up
Cited by 342Diabetes Treatment and ManagementPharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Emerging role of SGLT-2 inhibitors for the treatment of obesity

Open access
Pereira, Maria J., Eriksson, Jan W.·2019·Drugs
DOI 10.1007/s40265-019-1057-0PMC PMC6394798
Open this paper in CoChat — free accountOpen PDF

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductions in body weight and adiposity. The ability to reduce body weight is consistently observed in individuals taking SGLT2 inhibitors, but this weight loss is moderate due to counter-regulatory mechanisms striving to maintain body weight. This has prompted exploration of SGLT2 inhibitors in combination with other agents acting via decreased food intake, e.g., glucagon-like peptide 1 receptor agonists (GLP1-RAs). The bodyweight effects are promising, and together with the signs of prevention of cardiovascular and renal events, such combinations including SGLT2 inhibitors are appealing. The weight loss is clinically important, as most individuals with type 2 diabetes are overweight or obese, but also because there is an unmet need for safe, effective, and durable weight loss interventions in obese individuals without diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-019-1057-0

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • It has been postulated that dapagliflozin can reduce body weight by calorie loss through glycosuria and by reducing subcutaneous and visceral abdominal adipose tissue.

    “Besides, it has been postulated that dapagliflozin can reduce body weight by calorie loss through glycosuria and by reducing subcutaneous and visceral abdominal adipose tissue (Pereira and Eriksson, 2019;Zheng et al, 2021).”

    From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Pereira and Eriksson, 2019

    The Effects on Body Weight and Adiposity section says SGLT2 inhibitors cause weight loss through urinary glucose excretion and that weight loss is mainly due to reduced subcutaneous and visceral fat. However, the paper’s table reports reductions in those fat depots for dapagliflozin combined with exenatide, not dapagliflozin alone, so it does not establish the full claim specifically for dapagliflozin. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 101 · Cited by 342

Research works printed but not linked: 83

  1. [2]Martin-Rodriguez E Guillen-Grima F Marti A Brugos-Larumbe A Comorbidity associated with obesity in a large population: the APNA study Obesity research & clinical practice. 2015 9 5 435 447 10.1016/j.orcp.2015.04.003 25979684 · DOI
  2. [3]Sirtori A Brunani A Capodaglio P Berselli ME Villa V Ceriani F Patients with obesity-related comorbidities have higher disability compared with those without obesity-related comorbidities: results from a cross-sectional study Int J Rehabil Res 2016 39 1 63 69 10.1097/MRR.0000000000000146 26579698 · DOI
  3. [4]Simon GE Von Korff M Saunders K Miglioretti DL Crane PK van Belle G Association between obesity and psychiatric disorders in the US adult population Arch Gen Psychiatry 2006 63 7 824 830 10.1001/archpsyc.63.7.824 16818872 PMC1913935 · DOI · Paper page
  4. [5]Malnick SD Knobler H The medical complications of obesity QJM 2006 99 9 565 579 10.1093/qjmed/hcl085 16916862 · DOI · Paper page
  5. [9]Sjostrom L Peltonen M Jacobson P Sjostrom CD Karason K Wedel H Bariatric surgery and long-term cardiovascular events JAMA 2012 307 1 56 65 10.1001/jama.2011.1914 22215166 · DOI · Paper page
  6. [12]Wilding JP Combination therapy for obesity J Psychopharmacol. 2017 31 11 1503 1508 10.1177/0269881117737401 29132230 · DOI
  7. [14]Henry RR Klein EJ Han J Iqbal N Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: an Uncontrolled Open-Label Extension of the DURATION-1 Study Diabetes Technol Ther. 2016 18 11 677 686 10.1089/dia.2016.0107 27525540 PMC5124747 · DOI
  8. [15]Bolinder J Ljunggren O Johansson L Wilding J Langkilde AM Sjostrom CD Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes Metab 2014 16 2 159 169 10.1111/dom.12189 23906445 · DOI
  9. [16]Del Prato S Nauck M Duran-Garcia S Maffei L Rohwedder K Theuerkauf A Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data Diabetes Obes Metab 2015 17 6 581 590 10.1111/dom.12459 25735400 · DOI
  10. [17]Frias JP Guja C Hardy E Ahmed A Dong F Ohman P Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial The lancet Diabetes & endocrinology. 2016 4 12 1004 1016 10.1016/S2213-8587(16)30267-4 27651331 · DOI
  11. [18]Zaccardi F Htike ZZ Webb DR Khunti K Davies MJ Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: a Systematic Review and Network Meta-analysis Ann Intern Med 2016 164 2 102 113 10.7326/M15-1432 26642233 · DOI
  12. [20]Shyangdan DS Uthman OA Waugh N SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis BMJ Open 2016 6 2 e009417 10.1136/bmjopen-2015-009417 PMC4769433 26911584 · DOI
  13. [21]Lundkvist P, Pereira MJ, Katsogiannos P, Sjostrom CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in bodyweight, glycaemia, and blood pressure over 1 year. Diabetes Obes Metab. 2017. PMC5575470 28345814
  14. [22]Mearns ES Saulsberry WJ White CM Kohn CG Lemieux S Sihabout A Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis Diabet Med 2015 32 12 1530 1540 10.1111/dme.12837 26104021 · DOI
  15. [23]Ramirez-Rodriguez AM, Gonzalez-Ortiz M, Martinez-Abundis E. Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes. Exp Clin Endocrinol Diabetes. 2018. 30149417
  16. [24]Busch RS Kane MP Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes Postgrad Med 2017 129 7 686 697 10.1080/00325481.2017.1342509 28657399 · DOI
  17. [25]Vasilakou D Karagiannis T Athanasiadou E Mainou M Liakos A Bekiari E Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 2013 159 4 262 274 10.7326/0003-4819-159-4-201308200-00007 24026259 · DOI · Paper page
  18. [26]Zaccardi F Webb DR Htike ZZ Youssef D Khunti K Davies MJ Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis Diabetes Obes Metab 2016 18 8 783 794 10.1111/dom.12670 27059700 · DOI
  19. [27]Liu XY Zhang N Chen R Zhao JG Yu P Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years J Diabetes Complications 2015 29 8 1295 1303 10.1016/j.jdiacomp.2015.07.011 26365905 · DOI
  20. [28]Maruthur NM Tseng E Hutfless S Wilson LM Suarez-Cuervo C Berger Z Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: a Systematic Review and Meta-analysis Ann Intern Med 2016 164 11 740 751 10.7326/M15-2650 27088241 · DOI · Paper page
  21. [30]Lundkvist P Sjostrom CD Amini S Pereira MJ Johnsson E Eriksson JW Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes Diabetes Obes Metab 2017 19 1 49 60 10.1111/dom.12779 27550386 PMC5215525 · DOI · Paper page
  22. [31]Lundkvist P Pereira MJ Katsogiannos P Sjostrom CD Johnsson E Eriksson JW Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in body weight, glycaemia and blood pressure over 1 year Diabetes Obes Metab 2017 19 9 1276 1288 10.1111/dom.12954 28345814 PMC5575470 · DOI · Paper page
  23. [32]Monami M Nardini C Mannucci E Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials Diabetes Obes Metab 2014 16 5 457 466 10.1111/dom.12244 24320621 · DOI
  24. [33]Gerich JE Physiology of glucose homeostasis Diabetes Obes Metab 2000 2 6 345 350 10.1046/j.1463-1326.2000.00085.x 11225963 · DOI
  25. [35]Mearns ES Sobieraj DM White CM Saulsberry WJ Kohn CG Doleh Y Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis PLoS ONE 2015 10 4 e0125879 10.1371/journal.pone.0125879 25919293 PMC4412636 · DOI
  26. [37]Bolinder J Ljunggren O Johansson L Wilding J Langkilde AM Sjostrom CD Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes Metab 2014 16 2 159 169 10.1111/dom.12189 23906445 · DOI
  27. [38]Bailey CJ Morales Villegas EC Woo V Tang W Ptaszynska A List JF Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial Diabet Med 2015 32 4 531 541 10.1111/dme.12624 25381876 · DOI
  28. [39]Del Prato S Nauck M Duran-Garcia S Maffei L Rohwedder K Theuerkauf A Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data Diabetes Obes Metab 2015 17 6 581 590 10.1111/dom.12459 25735400 · DOI
  29. [40]Ferrannini G Hach T Crowe S Sanghvi A Hall KD Ferrannini E Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition Diabetes Care 2015 38 9 1730 1735 10.2337/dc15-0355 26180105 PMC4542276 · DOI
  30. [42]Hollander P Bays HE Rosenstock J Frustaci ME Fung A Vercruysse F Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: a Randomized Clinical Trial Diabetes Care 2017 40 5 632 639 10.2337/dc16-2427 28289041 · DOI · Paper page
  31. [43]Devenny JJ Godonis HE Harvey SJ Rooney S Cullen MJ Pelleymounter MA Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats Obesity. 2012 20 8 1645 1652 10.1038/oby.2012.59 22402735 · DOI · Paper page
  32. [44]Yokono M Takasu T Hayashizaki Y Mitsuoka K Kihara R Muramatsu Y SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats Eur J Pharmacol 2014 727 66 74 10.1016/j.ejphar.2014.01.040 24486393 · DOI
  33. [45]Ferrannini E Baldi S Frascerra S Astiarraga B Heise T Bizzotto R Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes Diabetes 2016 65 5 1190 1195 10.2337/db15-1356 26861783 · DOI
  34. [46]Xu L Nagata N Nagashimada M Zhuge F Ni Y Chen G SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice EBioMedicine. 2017 20 137 149 10.1016/j.ebiom.2017.05.028 28579299 PMC5478253 · DOI
  35. [47]Sugizaki T Zhu S Guo G Matsumoto A Zhao J Endo M Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality NPJ Aging Mech Dis. 2017 3 12 10.1038/s41514-017-0012-0 28900540 PMC5591191 · DOI
  36. [48]Greenberg AS Obin MS Obesity and the role of adipose tissue in inflammation and metabolism Am J Clin Nutr 2006 83 2 461S 465S 10.1093/ajcn/83.2.461S 16470013 · DOI
  37. [49]Neal B Perkovic V Mahaffey KW de Zeeuw D Fulcher G Erondu N Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N Engl J Med 2017 377 7 644 657 10.1056/NEJMoa1611925 28605608 · DOI · Paper page
  38. [51]Wiviott SD Raz I Bonaca MP Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2019 380 4 347 357 10.1056/NEJMoa1812389 30415602 · DOI · Paper page
  39. [52]Rajasekeran H Lytvyn Y Cherney DZ Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis Kidney Int 2016 89 3 524 526 10.1016/j.kint.2015.12.038 26880444 · DOI
  40. [53]Mudaliar S Alloju S Henry RR Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016 39 7 1115 1122 10.2337/dc16-0542 27289124 · DOI · Paper page
  41. [55]Wilson PW D’Agostino RB Sullivan L Parise H Kannel WB Overweight and obesity as determinants of cardiovascular risk: the Framingham experience Arch Intern Med 2002 162 16 1867 1872 10.1001/archinte.162.16.1867 12196085 · DOI · Paper page
  42. [56]Oliva RV Bakris GL Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors J Am Soc Hypertens. 2014 8 5 330 339 10.1016/j.jash.2014.02.003 24631482 · DOI
  43. [57]Sjostrom CD Hashemi M Sugg J Ptaszynska A Johnsson E Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels Diabetes Obes Metab 2015 17 8 809 812 10.1111/dom.12500 25997813 · DOI
  44. [59]Sano M A new class of drugs for heart failure: sGLT2 inhibitors reduce sympathetic overactivity J Cardiol 2018 71 5 471 476 10.1016/j.jjcc.2017.12.004 29415819 · DOI · Paper page
  45. [60]Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006. PMC4363087 25767285
  46. [61]Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K, For et al. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Prim Care Diabetes. 2018;12(3):265-83. 29482993
  47. [62]Wanner C EMPA-REG OUTCOME: the Nephrologist’s Point of View Am J Cardiol 2017 120 1S S59 S67 10.1016/j.amjcard.2017.05.012 28606346 · DOI
  48. [63]Fioretto P Del Prato S Buse JB Goldenberg R Giorgino F Reyner D Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study Diabetes Obes Metab 2018 20 11 2532 2540 10.1111/dom.13413 29888547 PMC6175614 · DOI · Paper page
  49. [64]Henry RR Thakkar P Tong C Polidori D Alba M Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Diabetes Care 2015 38 12 2258 2265 10.2337/dc15-1730 26486192 · DOI
  50. [65]Dandona P Mathieu C Phillip M Hansen L Griffen SC Tschope D Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial The lancet Diabetes & endocrinology. 2017 5 11 864 876 10.1016/S2213-8587(17)30308-X 28919061 · DOI
  51. [66]Garg SK Henry RR Banks P Buse JB Davies MJ Fulcher GR Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes N Engl J Med 2017 377 24 2337 2348 10.1056/NEJMoa1708337 28899222 · DOI · Paper page
  52. [67]Alsahli M Gerich JE Hypoglycemia in Patients with Diabetes and Renal Disease J Clin Med. 2015 4 5 948 964 10.3390/jcm4050948 26239457 PMC4470208 · DOI
  53. [69]Peters AL Buschur EO Buse JB Cohan P Diner JC Hirsch IB Euglycemic Diabetic Ketoacidosis: a Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition Diabetes Care 2015 38 9 1687 1693 10.2337/dc15-0843 26078479 PMC4542270 · DOI · Paper page
  54. [72]Ravussin Y Leibel RL Ferrante AW Jr A missing link in body weight homeostasis: the catabolic signal of the overfed state Cell Metab 2014 20 4 565 572 10.1016/j.cmet.2014.09.002 25295786 PMC4191848 · DOI
  55. [73]Pereira MJ Lundkvist P Kamble PG Lau J Martins JG Sjostrom CD A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: metabolic Effects and Markers Associated with Bodyweight Loss Diabetes Ther. 2018 9 4 1511 1532 10.1007/s13300-018-0449-6 29949016 PMC6064580 · DOI
  56. [74]Schafer SA Mussig K Staiger H Machicao F Stefan N Gallwitz B A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion Diabetologia 2009 52 6 1075 1082 10.1007/s00125-009-1344-5 19330314 · DOI
  57. [75]Enigk U Breitfeld J Schleinitz D Dietrich K Halbritter J Fischer-Rosinsky A Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis Pharmacogenomics. 2011 12 8 1119 1126 10.2217/pgs.11.69 21830867 · DOI
  58. [76]Zimdahl H Haupt A Brendel M Bour L Machicao F Salsali A Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes Pharmacogenet Genomics 2017 27 4 135 142 10.1097/FPC.0000000000000268 28134748 · DOI
  59. [77]Hall KD Sacks G Chandramohan D Chow CC Wang YC Gortmaker SL Quantification of the effect of energy imbalance on bodyweight Lancet 2011 378 9793 826 837 10.1016/S0140-6736(11)60812-X 21872751 PMC3880593 · DOI · Paper page
  60. [80]Citrome L Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out Int J Clin Pract 2014 68 12 1401 1405 10.1111/ijcp.12587 25418525 · DOI
  61. [81]Deol H Lekkakou L Viswanath AK Pappachan JM Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience Endocrine 2017 55 1 173 178 10.1007/s12020-016-1125-0 27696231 · DOI
  62. [82]Napolitano A, Miller S, Murgatroyd PR, Hussey E, Dobbins RL, Bullmore ET et al. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J Clin Transl Endocrinol. 2014;1(1):e3-e8. PMC5685025 29235586
  63. [83]Lundkvist P, Sjostrom CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab. 2016. PMC5215525 27550386
  64. [84]Bailey CJ Iqbal N T’Joen C List JF Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range Diabetes Obes Metab 2012 14 10 951 959 10.1111/j.1463-1326.2012.01659.x 22776824 · DOI
  65. [85]Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 2010 33 10 2217 2224 10.2337/dc10-0612 20566676 PMC2945163 · DOI
  66. [86]Ji L, Ma J, Li H, Mansfield TA, T’Joen C L, Iqbal N et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014;36(1):84-100 e9. 24378206
  67. [87]Kaku K Kiyosue A Inoue S Ueda N Tokudome T Yang J Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise Diabetes Obes Metab 2014 16 11 1102 1110 10.1111/dom.12325 24909293 · DOI
  68. [88]Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 2010 375 9733 2223 2233 10.1016/S0140-6736(10)60407-2 20609968 · DOI
  69. [89]Bailey CJ Gross JL Hennicken D Iqbal N Mansfield TA List JF Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial BMC Med. 2013 11 43 10.1186/1741-7015-11-43 23425012 PMC3606470 · DOI
  70. [91]Strojek K Yoon KH Hruba V Elze M Langkilde AM Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 10.1111/j.1463-1326.2011.01434.x 21672123 · DOI
  71. [92]Strojek K Yoon KH Hruba V Sugg J Langkilde AM Parikh S Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial Diabetes Ther. 2014 5 1 267 283 10.1007/s13300-014-0072-0 24920277 PMC4065289 · DOI
  72. [93]Nauck MA Del Prato S Meier JJ Duran-Garcia S Rohwedder K Elze M Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 10.2337/dc11-0606 21816980 PMC3161265 · DOI
  73. [94]Nauck MA Del Prato S Duran-Garcia S Rohwedder K Langkilde AM Sugg J Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin Diabetes Obes Metab 2014 16 11 1111 1120 10.1111/dom.12327 24919526 · DOI
  74. [95]Fulcher G Matthews DR Perkovic V de Zeeuw D Mahaffey KW Mathieu C Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes Diabetes Obes Metab 2016 18 1 82 91 10.1111/dom.12589 26450639 · DOI · Paper page
  75. [97]Jabbour SA, Hardy E, Sugg J, Parikh S, Study G Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 2014 37 3 740 750 10.2337/dc13-0467 24144654 · DOI
  76. [98]DeFronzo RA Lewin A Patel S Liu D Kaste R Woerle HJ Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin Diabetes Care 2015 38 3 384 393 10.2337/dc14-2364 25583754 · DOI
  77. [99]Pratley RE Eldor R Raji A Golm G Huyck SB Qiu Y Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial Diabetes Obes Metab 2018 20 5 1111 1120 10.1111/dom.13194 29266675 PMC5947297 · DOI
  78. [100]Rosenstock J Hansen L Zee P Li Y Cook W Hirshberg B Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes Care 2015 38 3 376 383 10.2337/dc14-1142 25352655 · DOI
  79. [101]Mathieu C Herrera Marmolejo M Gonzalez Gonzalez JG Hansen L Chen H Johnsson E Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes Diabetes Obes Metab 2016 18 11 1134 1137 10.1111/dom.12737 27385192 · DOI
  80. [102]Rosenstock J Vico M Wei L Salsali A List JF Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 2012 35 7 1473 1478 10.2337/dc11-1693 22446170 PMC3379599 · DOI
  81. [103]Kovacs CS Seshiah V Swallow R Jones R Rattunde H Woerle HJ Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 2014 16 2 147 158 10.1111/dom.12188 23906415 · DOI
  82. [104]Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S, Dapagliflozin 006 Study G. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124-36. 23911013
  83. [105]Rosenstock J Jelaska A Frappin G Salsali A Kim G Woerle HJ Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes Diabetes Care 2014 37 7 1815 1823 10.2337/dc13-3055 24929430 · DOI

Authors
Pereira, M. J., & Eriksson, J. W.
Affiliations
Uppsala University (SE)
Corresponding author
Eriksson, Jan W.
ORCID
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2019-01-30
Volume
79
Issue
3
Pages
219-230
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
DOI
10.1007/s40265-019-1057-0
PMC
PMC6394798
OpenAlex
W2911721172
Cited by
342
References
101
Citations by year
2026: 31 · 2025: 72 · 2024: 52 · 2023: 64 · 2022: 42 · 2021: 49 · 2020: 25 · 2019: 5 · 2012: 1
FWCI
24.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Drugs (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
Funders
  • AstraZeneca
  • Sanofi
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
SGLT2 inhibitors, obesity, weight loss, glycosuria, type 2 diabetes, GLP-1 receptor agonists, combination therapy, counter-regulatory mechanisms, cardiovascular events, renal events, adiposity
MeSH terms
Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Blood Glucose, Blood Pressure, Body Weight, Drug Therapy, Combination, Heart, Humans, Kidney, Obesity, Weight Loss, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review